Restructuring (Tables)

9 Months Ended

Sep. 29, 2024

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve

The following table summarizes the restructuring expenses for 2024 and 2023:

(Pre-tax Dollars in Millions)	Q3 2024	Q3 2023	Q3 YTD 2024	Q3 YTD 2023
Innovative Medicine Segment(1)	$19	149	100	424
MedTech Segment(2)	28	235	107	235
Total Programs	$47	384	207	659

(1)Included in Restructuring on the Consolidated Statement of Earnings for the fiscal 2023 and 2024

(2)The fiscal third quarter of 2024 included $22 million in Restructuring and $6 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal nine months of 2024 included $92 million in Restructuring and $15 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal third quarter and nine months of 2023 included $9 million in Restructuring and $226 million in Cost of products sold on the Consolidated Statement of Earnings